30 SEPTEMBER 2024 - We are disappointed by NICE’s draft decision not to recommend Cabotegravir long-acting (CAB-LA), an injectable PrEP option that could help increase PrEP uptake among women, Black African communities, and #marginalised communities. “CAB-LA has the potential to significantly benefit other groups, including women, homeless people, the prison population, transgender and gender diverse individuals, and others currently underserved by existing prevention optio